文献速递神经肿瘤

成人毛细胞型星形细胞瘤化疗的多中心回顾性队列研究

Chemotherapy in adult patients with pilocytic astrocytoma: a retrospective multicenter cohort study.
PubMed 文献 · J Neurooncol · 2025-10-15

全类型化疗客观缓解率为42%,中位无进展生存期20个月,中位总生存期49个月;青少年和年轻成人(<40岁)生存结局显著更优。结论认为化疗对不可切除的症状性成人毛细胞型星形细胞瘤有疾病控制意义,但治疗正转向BRAF/MEK抑制剂等靶向治疗。

要点

  • 成人毛细胞型星形细胞瘤化疗客观缓解率42%,中位PFS 20个月,中位OS 49个月。
  • 青少年和年轻成人(<40岁)接受化疗后生存结局显著更优。
  • 靶向治疗时代化疗仍可作为无可用分子靶点或靶向治疗失败时的选择。

核心结论

  • 化疗可为既往接受过治疗的不可切除症状性成人毛细胞型星形细胞瘤患者提供有意义的疾病控制。
  • 青少年和年轻成人(<40岁)化疗后生存结局显著更优。
  • 随着BRAF/MEK抑制剂等靶向治疗疗效与耐受性改善,治疗正从传统化疗和放疗转向靶向治疗。
  • 在未发现可操作分子靶点或靶向治疗失败时,化疗仍是青少年和年轻成人的可行选择。

研究设计与样本

  • 多中心回顾性队列研究,纳入荷兰八家医疗中心2006至2020年间接受化疗的成人(≥16岁)毛细胞型星形细胞瘤患者。
  • 疗效采用RAPNO标准进行中心评估,生存 outcomes 采用Kaplan-Meier法分析。

主要发现

  • 多数患者既往接受过治疗,包括放疗(n=19)和/或手术(n=17),从组织病理学诊断至化疗开始的中位间隔超过五年。
  • 替莫唑胺是最常用的化疗药物(64.5%)。
  • 全类型化疗的客观缓解率为42%,中位无进展生存期20个月,中位总生存期49个月。
  • 青少年和年轻成人(<40岁)生存结局显著更优。

关键数值与推荐

  • 疗效评估采用RAPNO标准。
  • 全类型化疗客观缓解率42%。
  • 中位无进展生存期20个月。
  • 中位总生存期49个月。
  • 替莫唑胺使用比例64.5%。

临床怎么用

  • 对于既往治疗后不可切除的症状性成人毛细胞型星形细胞瘤,化疗可作为疾病控制手段。
  • 青少年和年轻成人(<40岁)可从化疗中获得更优生存,可优先考虑。
  • 无可用分子靶点或靶向治疗失败时,化疗仍是可行选择。

局限性

  • 患者异质性较大,既往治疗包括放疗和/或手术。
  • 原文未报告化疗的具体方案分层疗效及安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pilocytic astrocytomas are circumscribed WHO grade I gliomas that predominantly affect children, although they also occur in adults. While maximal safe resection is standard treatment, until recently chemotherapy was often used in pediatrics with irresectable symptomatic tumors to delay radiotherapy. As evidence for this approach in adults is limited, we performed a multicenter retrospective cohort study on this subject. METHODS: Adult patients (≥ 16 years) treated with chemotherapy between 2006 and 2020 across eight Dutch medical centers were included. Treatment response was centrally assessed using RAPNO criteria and survival outcomes were analyzed using the Kaplan-Meier method. RESULTS: Thirty-one patients with pilocytic astrocytoma were included (median age 27 years). Most patients had received prior treatments, including radiotherapy (n = 19) and/or surgery (n = 17), with a median interval of over five years from histopathological diagnosis to the start of chemotherapy. Temozolomide was most frequently used (64.5%). The objective response rate for all types of chemotherapy was 42%, with a median progression-free survival of 20 months and a median overall survival of 49 months. Adolescents and young adults (< 40 years) showed significantly better survival outcomes. CONCLUSION: Chemotherapy offers meaningful disease control in adolescents and young adults with irresectable symptomatic pilocytic astrocytoma, after prior treatments. However, with the improved efficacy and tolerability of targeted treatments, such as BRAF/MEK inhibitors, treatment is shifting away from traditional chemotherapy and radiotherapy. Nevertheless, chemotherapy may still represent a viable treatment option in adolescent and young adults when no actionable molecular targets are identified or when targeted therapies have failed.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. van den Berg L, Wilbers J, de Vos FYFL, et al. Chemotherapy in adult patients with pilocytic astrocytoma: a retrospective multicenter cohort study. J Neurooncol. 2025. PMID: 41091241. doi:10.1007/s11060-025-05275-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。